North America Pain Management Drugs Market Overview:
The North America Pain Management Drugs Market size was valued at USD 11,968.20 MN in 2021 and reached USD 14,314.26 MN in 2025. It is anticipated to reach USD 18,345.24 MN by 2032, growing at a CAGR of 2.85% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2021-2024
Base Year
2025
Forecast Period
2025-2032
North America Pain Management Drugs Market Size 2025
USD 14,314.26 million
North America Pain Management Drugs Market, CAGR
2.85%
North America Pain Management Drugs Market Size 2032
USD 18,345.24 million
North America Pain Management Drugs Market Insights
Market growth is supported by chronic pain burden, arthritic pain prevalence, migraine treatment demand, postoperative pain management needs and rising preference for non-opioid and nonnarcotic analgesic options.
NSAIDs hold a strong position because arthritic pain, muscle sprain/strain, chronic back pain and postoperative pain require broad use of anti-inflammatory and analgesic therapy.
Anti-migraine Agents are gaining relevance as CGRP-targeted therapies, acute migraine drugs and preventive treatment options expand across retail and specialty pharmacy channels.
Retail Pharmacies remain the leading distribution channel because pain management drugs are commonly used for outpatient treatment, chronic refills and short-course acute pain therapy.
North America Pain Management Drugs Market Segment Insights
By drug class
By drug class, NSAIDs held a strong position in 2025 because they are widely used across arthritic pain, postoperative pain, chronic back pain, muscle sprain/strain, bone fracture and inflammatory pain conditions. Nonnarcotic Analgesics remain important because patients and providers continue to seek safer alternatives for mild to moderate pain. Anti-migraine Agents are gaining momentum through CGRP antagonists, triptans and newer acute or preventive therapies. Anticonvulsants and Antidepressants support neuropathic pain and fibromyalgia treatment, while Anesthetics remain important in postoperative and procedural pain. Opioids remain clinically relevant for cancer pain and severe acute pain but face prescribing controls, safety concerns and payer scrutiny.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By indication, Arthritic Pain held a strong position in 2025 due to high arthritis prevalence and long-term use of NSAIDs, nonnarcotic analgesics and adjunct therapies. Neuropathic Pain supports demand for anticonvulsants, antidepressants and selected specialty pain medicines. Cancer Pain continues to require opioids, non-opioids and adjuvant therapies under specialist oversight. Chronic Back Pain remains a major outpatient indication because it often requires multimodal treatment and recurring medication use. Postoperative Pain and Bone Fracture support short-course acute pain therapy, while Migraine creates demand for anti-migraine agents. Fibromyalgia, Muscle Sprain/Strain, Acute Appendicitis and Others contribute additional demand across hospital and retail settings.
By distribution channel
By distribution channel, Retail Pharmacies held the strongest position in 2025 because pain management drugs are frequently prescribed and refilled in outpatient settings. Retail channels dispense NSAIDs, nonnarcotic analgesics, anti-migraine agents, antidepressants, anticonvulsants and selected controlled pain therapies. Hospital Pharmacies remain important for postoperative pain, cancer pain, acute appendicitis, trauma, bone fracture, anesthesia-linked pain control and inpatient opioid stewardship. Online Pharmacies are gaining relevance through chronic refill management, home delivery and digital access to prescribed non-opioid pain medicines. Channel growth will favor providers that combine fast access, affordability, controlled-substance compliance and patient counseling.
Key Market Drivers
High chronic pain prevalence
High chronic pain prevalence represents a major growth driver for the North America Pain Management Drugs Market. Chronic pain creates sustained demand for NSAIDs, Anticonvulsants, Antidepressants, Opioids and Nonnarcotic Analgesics across outpatient and specialist care pathways. It also increases need for long-term refill management through Retail Pharmacies and Online Pharmacies.
NCHS reported that 24.3% of U.S. adults had chronic pain in 2023 and 8.5% had high-impact chronic pain that frequently limited life or work activities in the past three months. Chronic pain also increased with age, reaching 36.0% among adults 65 and older. This burden supports long-term demand across chronic back pain, neuropathic pain, fibromyalgia and other persistent pain conditions.
Arthritic pain and musculoskeletal disease burden
Arthritic pain and musculoskeletal disease burden support strong demand for NSAIDs, Nonnarcotic Analgesics and adjunctive therapies. Arthritis creates recurring pain, stiffness and activity limitation, which increases use of OTC and Rx pain medicines.
CDC estimates that 58.5 million U.S. adults have arthritis and 25.7 million report arthritis-attributable activity limitation, while CDC also reports that osteoarthritis affects about 33 million U.S. adults. This creates steady demand across arthritic pain, chronic back pain, muscle sprain/strain and bone fracture care. Retail Pharmacies benefit because many patients manage musculoskeletal pain through outpatient prescriptions, OTC therapy and recurring product purchases.
Non-opioid pain therapy innovation
Non-opioid pain therapy innovation is strengthening the market as regulators and manufacturers seek safer alternatives to opioids for acute and chronic pain pathways. Postoperative Pain, Bone Fracture, Muscle Sprain/Strain and other acute pain indications require effective analgesia without increasing opioid exposure where alternatives are appropriate.
FDA approved Journavx (suzetrigine) 50 milligram oral tablets in January 2025 as a first-in-class non-opioid analgesic for moderate to severe acute pain in adults, and the agency said it has long supported development of non-opioid pain treatments. FDA’s drug trial snapshot said the approval was based on evidence from three clinical trials involving 2,447 patients with moderate to severe acute pain after surgery or due to a nonsurgical condition. This driver supports demand for Nonnarcotic Analgesics and differentiated acute pain products.
Migraine treatment expansion
Migraine treatment expansion supports growth in Anti-migraine Agents and outpatient pharmacy channels. Migraine creates demand for acute treatment, preventive therapy and newer CGRP-targeted options that improve convenience and reduce treatment gaps. Supporting statement from government data: CDC reported that 4.3% of U.S. adults were bothered a lot by headache or migraine in the past three months in 2021, with higher prevalence among women than men. Supporting statement from key company data: Pfizer’s 2025 Form 10-K identified Nurtec ODT/Vydura as an approved therapy for acute treatment of migraine with or without aura in adults and reported revenue growth contribution from the product family. This driver supports Retail Pharmacies, Online Pharmacies and specialty migraine treatment pathways.
Key Trends and Opportunities
Non-opioid analgesics gain stronger role
Non-opioid analgesics are gaining a stronger role as clinicians seek pain control strategies that reduce opioid exposure. FDA’s 2025 approval of Journavx introduced a first-in-class oral non-opioid analgesic for moderate to severe acute pain in adults, showing regulatory momentum for new pain mechanisms. This trend supports Nonnarcotic Analgesics, NSAIDs and other non-opioid therapies used in postoperative pain, musculoskeletal pain and selected acute pain settings. It also creates opportunities for manufacturers that can show efficacy, safety and payer value. Adoption will depend on clinical experience, pricing, formulary access and physician familiarity.
CGRP-based migraine therapies expand
CGRP-based migraine therapies are expanding as patients seek acute and preventive treatments with improved tolerability and convenient administration. Anti-migraine Agents benefit from oral dissolving tablets, injectables, nasal products and preventive therapy options. FDA’s DailyMed label for Nurtec ODT shows use for acute treatment of migraine with or without aura in adults and preventive treatment of episodic migraine in adults. This trend supports Retail Pharmacies and Online Pharmacies because many migraine products are used outside hospital settings. Growth will depend on insurance coverage, prior authorization, patient affordability and physician adoption.
Online pharmacy access is expanding as chronic pain patients seek convenience, refill reminders and home delivery. Online Pharmacies can support non-opioid prescriptions, migraine therapies, antidepressants, anticonvulsants and selected chronic pain medicines when regulatory requirements are met. Retail Pharmacies remain central because many pain products require counseling, controlled-substance checks or urgent access. Digital refill models can improve therapy continuity for chronic back pain, fibromyalgia, migraine and neuropathic pain. This opportunity will grow where payers, prescribers and pharmacies integrate medication management with patient support. Controlled-substance safeguards will remain critical for opioid and high-risk medicine dispensing.
Key Market Challenges
Opioid safety concerns and prescribing restrictions
Opioid safety concerns and prescribing restrictions remain key challenges for the North America Pain Management Drugs Market. Opioids remain necessary for cancer pain, severe acute pain and selected postoperative settings, but prescribing is closely scrutinized because of addiction, overdose and diversion risk. Hospitals and payers increasingly use opioid stewardship programs, dose limits and prior authorization. Retail Pharmacies must manage controlled-substance compliance and patient safety. These restrictions can limit opioid market growth while shifting demand toward NSAIDs, Nonnarcotic Analgesics and multimodal treatment. Companies must align opioid products with responsible prescribing and risk management.
Generic competition and pricing pressure
Generic competition and pricing pressure affect many pain management drug classes. NSAIDs, antidepressants, anticonvulsants, opioids and several nonnarcotic analgesics have mature generic options that constrain branded revenue growth. Payers often prefer lower-cost therapies before covering premium anti-migraine agents or newer non-opioid products. Retail pharmacy substitution can accelerate price erosion in commoditized drug classes. Manufacturers must differentiate through novel mechanisms, improved dosing, lower side-effect burden or clearer clinical value. Pricing pressure will remain a major issue through 2032.
Safety and adherence issues in chronic pain
Safety and adherence issues can limit effective pain management. NSAIDs can carry gastrointestinal, renal and cardiovascular risks in selected patients, while anticonvulsants and antidepressants may cause tolerability issues. Anti-migraine agents can face adherence challenges when access, cost or prior authorization delays occur. Chronic pain patients may switch therapies frequently when relief is incomplete. Physicians and pharmacists must balance pain control with safety, comorbidities and polypharmacy. Companies that support patient education, adherence and risk mitigation will improve long-term therapy use.
Regional Analysis
United States
The United States leads the North America Pain Management Drugs Market due to high chronic pain burden, large arthritis population, broad retail pharmacy access and strong use of prescription and OTC pain therapies. Demand is strong across NSAIDs, Anti-migraine Agents, Anticonvulsants, Antidepressants, Opioids and Nonnarcotic Analgesics. Retail Pharmacies dominate outpatient dispensing, while Hospital Pharmacies manage postoperative pain, cancer pain, trauma, bone fracture and acute care pain. The U.S. also drives regulatory activity for non-opioid analgesics and migraine medicines. It is expected to remain the primary revenue contributor through 2032.
Canada
Canada represents a steady pain management drugs market supported by public health systems, private insurance, retail pharmacy access and guideline-based pain care. Demand is strong across arthritic pain, chronic back pain, migraine, postoperative pain and neuropathic pain. Retail Pharmacies support recurring medication access and patient counseling, while Hospital Pharmacies manage severe acute pain, cancer pain and postoperative care. Market access depends on provincial formularies, reimbursement decisions and opioid stewardship policy. Growth will remain steady as Canada balances chronic pain treatment needs with safer prescribing practices and broader use of non-opioid therapies.
Mexico
Mexico offers a smaller but expanding opportunity within North America. Demand is supported by musculoskeletal pain, migraine, postoperative pain, trauma, bone fracture, retail pharmacy access and private health care growth. NSAIDs, Nonnarcotic Analgesics and selected prescription pain medicines remain important because affordability shapes treatment decisions. Hospital Pharmacies support acute and surgical pain management, while Online Pharmacies are emerging through digital access and home delivery. Opioid access remains more constrained than in the U.S., which supports demand for non-opioid options. Growth will depend on diagnosis, affordability, pharmacy reach and physician prescribing patterns.
Report Attribute Details
Report Attribute
Details
Historical Period
2021–2024
Base Year
2025
Forecast Period
2025–2032
Market Size in 2021
USD 11,968.20 MN
Market Size in 2025
USD 14,314.26 MN
Market Size in 2032
USD 18,345.24 MN
CAGR
2.85%
Segments Covered
Drug Class, Indication, Distribution Channel and Geography
Key Companies Covered
Johnson & Johnson Services Inc, Novartis AG, Viatris Inc., GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co. Inc., Abbott Laboratories, Cipla Ltd, Purdue Pharma L.P. and Endo Health Solutions, Inc.
Market Segmentations
By Drug Class
NSAIDs
Anesthetics
Anticonvulsants
Anti-migraine Agents
Antidepressants
Opioids
Nonnarcotic Analgesics
By Indication
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia
Muscle Sprain/Strain
Bone Fracture
Acute Appendicitis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Players
Johnson & Johnson Services Inc
Novartis AG
Viatris Inc.
GlaxoSmithKline Plc
Pfizer, Inc.
Merck & Co. Inc.
Abbott Laboratories
Cipla Ltd
Purdue Pharma L.P.
Endo Health Solutions, Inc.
Recent Developments
In January 2025, FDA approved Journavx, a first-in-class non-opioid analgesic for moderate to severe acute pain in adults. The agency described the approval as a milestone in acute pain management and part of broader efforts to support alternatives to opioids.
In 2025, FDA’s drug trial snapshot for Journavx reported that approval was supported by three clinical trials involving 2,447 patients with moderate to severe acute pain after surgery or due to a nonsurgical condition.
In 2025, Pfizer’s Form 10-K identified Nurtec ODT/Vydura as an approved acute migraine therapy and included it among products contributing to worldwide growth.
In 2026, DailyMed reflected updated Nurtec ODT labeling for acute migraine treatment and preventive treatment of episodic migraine in adults, with Pfizer Laboratories listed as packager.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on drug class, indication, distribution channel and geography. It details leading market players, providing an overview of their business positioning, pain management portfolios, migraine therapies, non-opioid products, opioid exposure, OTC presence and strategic relevance in the North America Pain Management Drugs Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines chronic pain prevalence, arthritic pain burden, non-opioid innovation, migraine treatment expansion, retail pharmacy access and opioid stewardship as major factors shaping market development. The report assesses the impact of opioid safety concerns, generic competition, pricing pressure, adherence issues and payer controls on market growth. It provides strategic recommendations for pharmaceutical companies, hospital systems, retail pharmacy networks, online pharmacies, payers, distributors, investors and new entrants seeking to navigate North America’s pain management drugs ecosystem.
Future Outlook
Demand for pain management drugs will continue to rise as chronic pain, arthritis, migraine and postoperative pain remain major treatment needs.
NSAIDs will remain a major drug class due to broad use in arthritic pain, musculoskeletal pain and postoperative pain.
Nonnarcotic Analgesics will gain relevance as clinicians and payers support opioid-sparing pain management.
Anti-migraine Agents will grow as CGRP-targeted drugs and newer acute therapies expand use.
Anticonvulsants and Antidepressants will remain important for neuropathic pain and fibromyalgia management.
Opioids will remain clinically relevant for cancer pain and severe acute pain but will face continued prescribing controls.
Retail Pharmacies will remain the leading distribution channel due to chronic refills and outpatient pain treatment.
Hospital Pharmacies will remain important for postoperative pain, cancer pain, fractures, anesthesia-linked treatment and acute care.
Online Pharmacies will gain share as chronic pain patients use digital refill management and home delivery.
Competition will increase as companies compete on non-opioid innovation, migraine access, generic pricing, safety profile, payer coverage and patient support.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
Chapter No. 1: Introduction
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. USP and Key Offerings
1.2. Key Benefits for Stakeholders
1.3. Target Audience
Chapter No. 2: Executive Summary
Chapter No. 3: North America Pain Management Drugs Market forces and industry pulse
3.1. Introduction
3.2. Catalysts of Expansion – Key Market Drivers
3.2.1. High chronic pain prevalence
3.2.2. Arthritic pain and musculoskeletal disease burden
3.2.3. Non-opioid pain therapy innovation
3.2.4. Migraine treatment expansion
3.3. Market Restraints
3.3.1. Opioid safety concerns and prescribing restrictions
3.3.2. Generic competition and pricing pressure
3.3.3. Safety and adherence issues in chronic pain
3.4. Untapped Horizons – Growth Potential and Opportunities; Strategic Navigation – Industry Frameworks
3.4.1. Non-opioid analgesics gain stronger role
3.4.2. CGRP-based migraine therapies expand
3.4.3. Online pharmacy access supports chronic pain refills
Chapter No. 4: Competition Analysis
4.1. Company Market Share Analysis
4.1.1. North America Pain Management Drugs Market Company Revenue Market Share, 2025
4.2. Strategic Developments
4.3. Competitive Dashboard
4.4. Company Assessment Metrics, 2025
Chapter No. 5: North America Market Analysis, Insights and Forecast, by Drug Class
Chapter No. 6: North America Market Analysis, Insights and Forecast, by Indication
Chapter No. 7: North America Market Analysis, Insights and Forecast, by Distribution Channel
Chapter No. 8: North America Market Analysis, Insights and Forecast, by Geography
8.1. United States
8.2. Canada
8.3. Mexico
Chapter No. 9: Company Profile
9.1. Johnson & Johnson Services Inc
9.2. Novartis AG
9.3. Viatris Inc.
9.4. GlaxoSmithKline Plc
9.5. Pfizer, Inc.
9.6. Merck & Co. Inc.
9.7. Abbott Laboratories
9.8. Cipla Ltd
9.9. Purdue Pharma L.P.
9.10. Endo Health Solutions, Inc.
List of figures
Fig No. 1: North America Pain Management Drugs Market Revenue Share, by Drug Class, 2025 and 2032
Fig No. 2: Market Attractiveness Analysis, by Drug Class
Fig No. 3: Incremental Revenue Growth Opportunity by Drug Class, 2025–2032
Fig No. 4: North America Pain Management Drugs Market Revenue Share, by Indication, 2025 and 2032
Fig No. 5: Incremental Revenue Growth Opportunity by Indication, 2025–2032
Fig No. 6: North America Pain Management Drugs Market Revenue Share, by Distribution Channel, 2025 and 2032
Fig No. 7: North America Pain Management Drugs Market Revenue Share, by Geography, 2025 and 2032
Fig No. 8: Market Attractiveness Analysis, by Geography
List of tables
Table No. 1: North America Pain Management Drugs Market Revenue, by Drug Class, 2021–2025 (USD MN)
Table No. 2: North America Pain Management Drugs Market Revenue, by Drug Class, 2026–2032 (USD MN)
Table No. 3: North America Pain Management Drugs Market Revenue, by Indication, 2021–2025 (USD MN)
Table No. 4: North America Pain Management Drugs Market Revenue, by Indication, 2026–2032 (USD MN)
Table No. 5: North America Pain Management Drugs Market Revenue, by Distribution Channel, 2021–2025 (USD MN)
Table No. 6: North America Pain Management Drugs Market Revenue, by Distribution Channel, 2026–2032 (USD MN)
Table No. 7: North America Pain Management Drugs Market Revenue, by Geography, 2021–2025 (USD MN)
Table No. 8: North America Pain Management Drugs Market Revenue, by Geography, 2026–2032 (USD MN)
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the North America Pain Management Drugs Market and what is its projected size in 2032?
The North America Pain Management Drugs Market was valued at USD 14,314.26 MN in 2025 and is projected to reach USD 18,345.24 MN by 2032.
At what CAGR is the North America Pain Management Drugs Market projected to grow?
The North America Pain Management Drugs Market is projected to grow at a CAGR of 2.85% during the forecast period.
Which drug class segment is expected to lead the market?
NSAIDs are expected to hold a strong position because they are widely used across arthritic pain, chronic back pain, postoperative pain, muscle sprain/strain and other inflammatory pain conditions.
Which indication supports strong market demand?
Arthritic Pain supports strong market demand because arthritis creates recurring pain, stiffness and activity limitation that require long-term medication use.
Which distribution channel holds the strongest position?
Retail Pharmacies hold the strongest position because pain management drugs are commonly prescribed, refilled and purchased in outpatient settings.
Who are the leading companies in the market?
The leading companies include Johnson & Johnson Services Inc, Novartis AG, Viatris Inc., GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co. Inc., Abbott Laboratories, Cipla Ltd, Purdue Pharma L.P. and Endo Health Solutions, Inc.
Which geography leads the North America market?
The United States leads the market due to high chronic pain burden, large arthritis population, broad retail pharmacy access and strong use of prescription and OTC pain therapies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Europe Dermatology Drugs Market size was valued at USD 8,384.62 MN in 2021 and reached USD 10,909.79 MN in 2025. It is anticipated to reach USD 17,933.36 MN by 2032, growing at a CAGR of 6.18% during the forecast period.
The North America Respiratory Drugs Market size was valued at USD 4,603.33 MN in 2021 and reached USD 5,912.29 MN in 2025. It is anticipated to reach USD 8,990.65 MN by 2032, growing at a CAGR of 5.07% during the forecast period.
The North America CNS Drugs Market size was valued at USD 29,971.81 MN in 2021 and reached USD 39,376.62 MN in 2025. It is anticipated to reach USD 64,694.22 MN by 2032, growing at a CAGR of 6.13% during the forecast period.
The Asia Pacific Gastrointestinal Drugs Market size was valued at USD 14,076.07 MN in 2021 and reached USD 18,379.23 MN in 2025. It is anticipated to reach USD 27,675.57 MN by 2032, growing at a CAGR of 4.86% during the forecast period.
The North America Immunology Drugs Market size was valued at USD 23,174.02 MN in 2021 and reached USD 34,194.85 MN in 2025. It is anticipated to reach USD 70,564.69 MN by 2032, growing at a CAGR of 9.11% during the forecast period.
The Europe Anticancer Drugs/Oncology Drugs Market size was valued at USD 52,704.85 MN in 2021 and reached USD 71,835.97 MN in 2025. It is anticipated to reach USD 125,841.34 MN by 2032, growing at a CAGR of 8.34% during the forecast period.
The North America Antidiabetics Drug Market size was valued at USD 18,811.60 MN in 2021 and reached USD 25,029.65 MN in 2025. It is anticipated to reach USD 42,563.34 MN by 2032, growing at a CAGR of 6.60% during the forecast period.
The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size was estimated at USD 11,280.60 million in 2025 and is expected to reach USD 15,527.66 million by 2032, growing at a CAGR of 5.47% from 2025 to 2032.
The Diphenhydramine Market size was estimated at USD 1,680.45 million in 2025 and is expected to reach USD 2,204.77 million by 2032, growing at a CAGR of 4.63% from 2025 to 2032.
The Intraosseous Devices Market size was valued at USD 448 million in 2024 and is anticipated to reach USD 612.55 million by 2032, growing at a CAGR of 3.98% during the forecast period.
The Dilated Cardiomyopathy Therapeutic Market size was estimated at USD 5,240.95 million in 2025 and is expected to reach USD 8,025.37 million by 2032, growing at a CAGR of 7.36% from 2025 to 2032.
The Divalproex Sodium Market size was estimated at USD 1,860.58 million in 2025 and is expected to reach USD 2,453.73 million by 2032, growing at a CAGR of 4.72% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
